Patent ID: 8952048
Filing Date: 2015-02-10
Classification: A61K,A61P,G01N

Abstract:
1. A method of treating an allergy or an autoimmune disease selected from the group consisting of systemic lupus erthyematosus (SLE), rheumatoid arthritis, and Sjogren's syndrome in a patient in need thereof, comprising the step of administering to said patient an agent that is 5-nitro-6,7,8,9-tetrahydro-1H-benzo[g]indole-2,3-dione 3-oxime (NS-102), wherein said agent is administered in a form and under conditions which permit binding to a kainate receptor (KAR), and which prevent or reduce glutamate binding to said KAR, so as to reduce B cell proliferation in said patient.